Hydrophilic and lipophilic silibinin pro-forms

A pharmaceutical composition suitable for topical or oral administration in an individual, said composition comprising a hydrophilic silibinin pro-form and a pharmaceutically acceptable carrier, wherein said silibinin pro-form has the formula:

• 4
• wherein
• one or more of R1, and R2, and R3 are independently selected from the group consisting of cationic esters, anionic esters, neutral esters, and H.

A lipophilic silibinin pro-form of the formula

• 5
• wherein
• one or more of R1, and R2, and R3 are independently selected from the group consisting of aliphatic acid residues, aromatic acid residues, and H.

A pharmaceutical composition suitable for topical or oral administration in an individual, said composition comprising a lipophilic silibinin pro-form and a pharmaceutically acceptable carrier, wherein said silibinin pro-form has the formula:

• 6
• wherein
• one or more of R1, and R2, and R3 are independently selected from the group consisting of aliphatic acid residues, aromatic acid residues, and H.

A method of treating a subject having or at risk of having a cell proliferative disorder, said method comprising administering to the subject a therapeutically effective amount of a silibinin pro-form.

A method of decreasing oxidative stress in a subject having a disorder associated with oxidative stress, said method comprising administering to the subject a therapeutically effective amount of a silibinin pro-form.

A method of treating a subject having or at risk of having a disorder associated with sebaceous gland activity, said method comprising adminstering to the subject a therapeutically effective amount of a silibinin pro-form.

A method of treating a subject having or at risk of having a cardiovascular disorder, said method comprising administering to the subject a therapeutically effective amount of a silibinin pro-form.